Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Feb. 7, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined…
84,350€
-7,41%
Echtzeit-Aktienkurs Blueprint Medicines Corp.
Bid:
Ask:
Nachrichten zur Blueprint Medicines Corp. Aktie
Can Blueprint Medicines (BPMC) Climb 61.38% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 61.4% in Blueprint Medicines (BPMC).…
Blueprint Medicines Gets FDA Priority Review for Ayvakit in Indolent Systemic Mastocytosis >BPMC
Blueprint Medicines Gets FDA Priority Review for Ayvakit in Indolent Systemic Mastocytosis >BPMC...…
Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis
-- FDA grants priority review and sets PDUFA action date of May 22, 2023 -- CAMBRIDGE, Mass., Jan. 23, 2023…
Form 8-K Blueprint Medicines Corp For: Jan 06
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors
CAMBRIDGE, Mass., Jan. 6, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of John Tsai, M.D.,…
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Jan. 4, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined…
Form 8-K Blueprint Medicines Corp For: Dec 23
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Where Blueprint Medicines Stands With Analysts
Latest Ratings for BPMC
DateFirmActionFromTo Mar 2022StifelMaintainsBuy Mar 2022CitigroupInitiates Coverage OnNeutral Feb 2022SVB LeerinkDowngradesOutperformMarket Perform
…
Blueprint Medicines Reports Clinical Data Highlighting Leadership in Developing Targeted Treatment Options for Patients with Systemic Mastocytosis
-- 95 percent confirmed overall response rate and 37 percent confirmed complete remission rate in treatment-naïve patients with SM-AHN, the…
Insiderhandel: Aufsichtsrat verkauft Aktien von Blueprint Medicines im Wert von 1.001.800$
Albers, Jeffrey W. - Aufsichtsrat - Tag der Transaktion: 2022-12-05...…
Form 8-K Blueprint Medicines Corp For: Dec 06
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Dec. 5, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined…
Blueprint Medicines (BPMC) Up 3.7% Since Last Earnings Report: Can It Continue?
Blueprint Medicines (BPMC) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…
Blueprint Medicines (BPMC) Files Ayvakit sNDA for Indolent SM
Blueprint Medicines (BPMC) submits a supplemental new drug application for its lead drug, Ayvakit, for the treatment of indolent systemic…
Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis
-- Company to present registrational PIONEER trial results at 2023 AAAAI Annual Meeting -- CAMBRIDGE, Mass., Nov. 22, 2022 /PRNewswire/…
Blueprint Medicines to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 9, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined…
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Nov. 4, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined…
Blueprint Medicines (BPMC) Q3 Earnings & Revenues Top Mark
Blueprint Medicines (BPMC) earnings and revenues trump estimates for the third quarter of 2022. The company lowers product revenue guidance…
Form 10-Q Blueprint Medicines Corp For: Sep 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Blueprint Medicines GAAP EPS of -$2.23 beats by $0.28, revenue of $65.97M beats by $22.09M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Oct. 6, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined…
Insiderhandel: PRESIDENT, R & D verkauft Aktien von Blueprint Medicines im Wert von 234.002$
Namouni, Fouad - Vorstand - Tag der Transaktion: 2022-10-04...…
Will Ayvakit Aid Blueprint Medicines (BPMC) Amid Rivalry?
Blueprint Medicines (BPMC) expects its lead drug, Ayvakit, which is approved to treat rare cancer and other rare diseases, to…